An observational study of plasma vascular endothelial growth factors (vegf) a and d expression in non-localized prostate cancer

Brandon P. Verdoorn, Changyong Feng, William A. Ricke, Deepak M. Sahasrabudhe, Deepak Kilari, Manish Kohli

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The aim of the study was to measure plasma levels of the vascular endothelial growth factors (VEGF) A and D in serially collected blood specimens from non-localized prostate cancer (PCa) subjects. Methods: Plasma VEGF A and D levels were measured in two serial specimens 3-6 months apart in two groups of non-localized stage PCa patients. Group 1 was comprised of patients with biochemical relapse after localized PCa treatments and/or patients with clinically metastatic hormone-sensitive stage PCa prior to receiving hormonal therapy. Group 2 included patients failing hormonal therapy for non-localized hormone-sensitive stage PCa. VEGF A and D levels were compared within each cancer group between the two time-points using the Wilcoxon Rank Sum test. Results: At the first time-point in Group 1 (n=. 46), median VEGF-A and D levels were measured at 5.2 (pg/ml) (range = 0-97) and 319 (range = 172-780) (pg/ml). For Group 2 (n=34) VEGF-A level was 9.6 pg/ml (range = 0-78) and VEGF-D level was 377 pg/ml (range = 243-989) for the first measurement. Median time-period for the serial second specimen was 189 days in Group 1 and 84 days in Group 2. At the second time-point, in Group 1, VEGF-A levels were 0.0 pg/ml (P=. 0.0002) while VEGF-D increased to 349 pg/ml (P=. 0.002). For Group 2 patients at the second time-point, median VEGF-A was 0.0 pg/ml (P=. 1.0) and VEGF-D was measured at 442 pg/ml (P=. 0.008). Conclusions: Higher plasma VEGF-D than VEGF-A expression in advanced PCa stages suggests a greater role for VEGF-D dependent lymph angiogenesis in advanced stage PCa, which needs further evaluation.

Original languageEnglish (US)
Pages (from-to)182-189
Number of pages8
JournalJournal of Men's Health
Volume9
Issue number3
DOIs
StatePublished - Sep 2012

Fingerprint

Vascular Endothelial Growth Factors
Vascular Endothelial Growth Factor D
Observational Studies
Prostatic Neoplasms
Vascular Endothelial Growth Factor A
Nonparametric Statistics
Hormones
Lymph
Therapeutics

Keywords

  • Angiogenesis
  • Chemo-hormonal treatments
  • Prostate cancer
  • VEGF

ASJC Scopus subject areas

  • Medicine(all)
  • Urology

Cite this

An observational study of plasma vascular endothelial growth factors (vegf) a and d expression in non-localized prostate cancer. / Verdoorn, Brandon P.; Feng, Changyong; Ricke, William A.; Sahasrabudhe, Deepak M.; Kilari, Deepak; Kohli, Manish.

In: Journal of Men's Health, Vol. 9, No. 3, 09.2012, p. 182-189.

Research output: Contribution to journalArticle

Verdoorn, Brandon P. ; Feng, Changyong ; Ricke, William A. ; Sahasrabudhe, Deepak M. ; Kilari, Deepak ; Kohli, Manish. / An observational study of plasma vascular endothelial growth factors (vegf) a and d expression in non-localized prostate cancer. In: Journal of Men's Health. 2012 ; Vol. 9, No. 3. pp. 182-189.
@article{a81def07e2bf4d2187e3a0c5d3740d12,
title = "An observational study of plasma vascular endothelial growth factors (vegf) a and d expression in non-localized prostate cancer",
abstract = "Background: The aim of the study was to measure plasma levels of the vascular endothelial growth factors (VEGF) A and D in serially collected blood specimens from non-localized prostate cancer (PCa) subjects. Methods: Plasma VEGF A and D levels were measured in two serial specimens 3-6 months apart in two groups of non-localized stage PCa patients. Group 1 was comprised of patients with biochemical relapse after localized PCa treatments and/or patients with clinically metastatic hormone-sensitive stage PCa prior to receiving hormonal therapy. Group 2 included patients failing hormonal therapy for non-localized hormone-sensitive stage PCa. VEGF A and D levels were compared within each cancer group between the two time-points using the Wilcoxon Rank Sum test. Results: At the first time-point in Group 1 (n=. 46), median VEGF-A and D levels were measured at 5.2 (pg/ml) (range = 0-97) and 319 (range = 172-780) (pg/ml). For Group 2 (n=34) VEGF-A level was 9.6 pg/ml (range = 0-78) and VEGF-D level was 377 pg/ml (range = 243-989) for the first measurement. Median time-period for the serial second specimen was 189 days in Group 1 and 84 days in Group 2. At the second time-point, in Group 1, VEGF-A levels were 0.0 pg/ml (P=. 0.0002) while VEGF-D increased to 349 pg/ml (P=. 0.002). For Group 2 patients at the second time-point, median VEGF-A was 0.0 pg/ml (P=. 1.0) and VEGF-D was measured at 442 pg/ml (P=. 0.008). Conclusions: Higher plasma VEGF-D than VEGF-A expression in advanced PCa stages suggests a greater role for VEGF-D dependent lymph angiogenesis in advanced stage PCa, which needs further evaluation.",
keywords = "Angiogenesis, Chemo-hormonal treatments, Prostate cancer, VEGF",
author = "Verdoorn, {Brandon P.} and Changyong Feng and Ricke, {William A.} and Sahasrabudhe, {Deepak M.} and Deepak Kilari and Manish Kohli",
year = "2012",
month = "9",
doi = "10.1016/j.jomh.2012.04.003",
language = "English (US)",
volume = "9",
pages = "182--189",
journal = "Journal of Men's Health and Gender",
issn = "1875-6867",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - An observational study of plasma vascular endothelial growth factors (vegf) a and d expression in non-localized prostate cancer

AU - Verdoorn, Brandon P.

AU - Feng, Changyong

AU - Ricke, William A.

AU - Sahasrabudhe, Deepak M.

AU - Kilari, Deepak

AU - Kohli, Manish

PY - 2012/9

Y1 - 2012/9

N2 - Background: The aim of the study was to measure plasma levels of the vascular endothelial growth factors (VEGF) A and D in serially collected blood specimens from non-localized prostate cancer (PCa) subjects. Methods: Plasma VEGF A and D levels were measured in two serial specimens 3-6 months apart in two groups of non-localized stage PCa patients. Group 1 was comprised of patients with biochemical relapse after localized PCa treatments and/or patients with clinically metastatic hormone-sensitive stage PCa prior to receiving hormonal therapy. Group 2 included patients failing hormonal therapy for non-localized hormone-sensitive stage PCa. VEGF A and D levels were compared within each cancer group between the two time-points using the Wilcoxon Rank Sum test. Results: At the first time-point in Group 1 (n=. 46), median VEGF-A and D levels were measured at 5.2 (pg/ml) (range = 0-97) and 319 (range = 172-780) (pg/ml). For Group 2 (n=34) VEGF-A level was 9.6 pg/ml (range = 0-78) and VEGF-D level was 377 pg/ml (range = 243-989) for the first measurement. Median time-period for the serial second specimen was 189 days in Group 1 and 84 days in Group 2. At the second time-point, in Group 1, VEGF-A levels were 0.0 pg/ml (P=. 0.0002) while VEGF-D increased to 349 pg/ml (P=. 0.002). For Group 2 patients at the second time-point, median VEGF-A was 0.0 pg/ml (P=. 1.0) and VEGF-D was measured at 442 pg/ml (P=. 0.008). Conclusions: Higher plasma VEGF-D than VEGF-A expression in advanced PCa stages suggests a greater role for VEGF-D dependent lymph angiogenesis in advanced stage PCa, which needs further evaluation.

AB - Background: The aim of the study was to measure plasma levels of the vascular endothelial growth factors (VEGF) A and D in serially collected blood specimens from non-localized prostate cancer (PCa) subjects. Methods: Plasma VEGF A and D levels were measured in two serial specimens 3-6 months apart in two groups of non-localized stage PCa patients. Group 1 was comprised of patients with biochemical relapse after localized PCa treatments and/or patients with clinically metastatic hormone-sensitive stage PCa prior to receiving hormonal therapy. Group 2 included patients failing hormonal therapy for non-localized hormone-sensitive stage PCa. VEGF A and D levels were compared within each cancer group between the two time-points using the Wilcoxon Rank Sum test. Results: At the first time-point in Group 1 (n=. 46), median VEGF-A and D levels were measured at 5.2 (pg/ml) (range = 0-97) and 319 (range = 172-780) (pg/ml). For Group 2 (n=34) VEGF-A level was 9.6 pg/ml (range = 0-78) and VEGF-D level was 377 pg/ml (range = 243-989) for the first measurement. Median time-period for the serial second specimen was 189 days in Group 1 and 84 days in Group 2. At the second time-point, in Group 1, VEGF-A levels were 0.0 pg/ml (P=. 0.0002) while VEGF-D increased to 349 pg/ml (P=. 0.002). For Group 2 patients at the second time-point, median VEGF-A was 0.0 pg/ml (P=. 1.0) and VEGF-D was measured at 442 pg/ml (P=. 0.008). Conclusions: Higher plasma VEGF-D than VEGF-A expression in advanced PCa stages suggests a greater role for VEGF-D dependent lymph angiogenesis in advanced stage PCa, which needs further evaluation.

KW - Angiogenesis

KW - Chemo-hormonal treatments

KW - Prostate cancer

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84865162164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865162164&partnerID=8YFLogxK

U2 - 10.1016/j.jomh.2012.04.003

DO - 10.1016/j.jomh.2012.04.003

M3 - Article

AN - SCOPUS:84865162164

VL - 9

SP - 182

EP - 189

JO - Journal of Men's Health and Gender

JF - Journal of Men's Health and Gender

SN - 1875-6867

IS - 3

ER -